These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
250 related articles for article (PubMed ID: 33712541)
41. Clinical Spectrum of Villarreal-Molina T; García-Ordóñez GP; Reyes-Quintero ÁE; Domínguez-Pérez M; Jacobo-Albavera L; Nava S; Carnevale A; Medeiros-Domingo A; Iturralde P Genes (Basel); 2021 Dec; 13(1):. PubMed ID: 35052356 [TBL] [Abstract][Full Text] [Related]
42. Enhanced Classification of Brugada Syndrome-Associated and Long-QT Syndrome-Associated Genetic Variants in the SCN5A-Encoded Na(v)1.5 Cardiac Sodium Channel. Kapplinger JD; Giudicessi JR; Ye D; Tester DJ; Callis TE; Valdivia CR; Makielski JC; Wilde AA; Ackerman MJ Circ Cardiovasc Genet; 2015 Aug; 8(4):582-95. PubMed ID: 25904541 [TBL] [Abstract][Full Text] [Related]
43. Functional Consequences of the Casini S; Albesa M; Wang Z; Portero V; Ross-Kaschitza D; Rougier JS; Marchal GA; Chung WK; Bezzina CR; Abriel H; Remme CA Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31614475 [TBL] [Abstract][Full Text] [Related]
44. Mexiletine rescues a mixed biophysical phenotype of the cardiac sodium channel arising from the SCN5A mutation, N406K, found in LQT3 patients. Hu RM; Tester DJ; Li R; Sun T; Peterson BZ; Ackerman MJ; Makielski JC; Tan BH Channels (Austin); 2018; 12(1):176-186. PubMed ID: 29983085 [TBL] [Abstract][Full Text] [Related]
45. Human iPS cell model of type 3 long QT syndrome recapitulates drug-based phenotype correction. Malan D; Zhang M; Stallmeyer B; Müller J; Fleischmann BK; Schulze-Bahr E; Sasse P; Greber B Basic Res Cardiol; 2016 Mar; 111(2):14. PubMed ID: 26803770 [TBL] [Abstract][Full Text] [Related]
46. Congenital long-QT syndrome caused by a novel mutation in a conserved acidic domain of the cardiac Na+ channel. Wei J; Wang DW; Alings M; Fish F; Wathen M; Roden DM; George AL Circulation; 1999 Jun; 99(24):3165-71. PubMed ID: 10377081 [TBL] [Abstract][Full Text] [Related]
47. Trafficking and localisation to the plasma membrane of Na Dulsat G; Palomeras S; Cortada E; Riuró H; Brugada R; Vergés M Biol Cell; 2017 Jul; 109(7):273-291. PubMed ID: 28597987 [TBL] [Abstract][Full Text] [Related]
49. Structural basis for voltage-sensor trapping of the cardiac sodium channel by a deathstalker scorpion toxin. Jiang D; Tonggu L; Gamal El-Din TM; Banh R; Pomès R; Zheng N; Catterall WA Nat Commun; 2021 Jan; 12(1):128. PubMed ID: 33397917 [TBL] [Abstract][Full Text] [Related]
50. Crystal structures of Ca Gardill BR; Rivera-Acevedo RE; Tung CC; Van Petegem F Proc Natl Acad Sci U S A; 2019 May; 116(22):10763-10772. PubMed ID: 31072926 [TBL] [Abstract][Full Text] [Related]
51. Pilsicainide Administration Unmasks a Phenotype of Brugada Syndrome in a Patient with Overlap Syndrome due to the E1784K SCN5A Mutation. Hasebe H; Yokoya T; Murakoshi N; Kurebayashi N Intern Med; 2020 Jan; 59(1):83-87. PubMed ID: 31484910 [TBL] [Abstract][Full Text] [Related]
52. Investigations of the Navβ1b sodium channel subunit in human ventricle; functional characterization of the H162P Brugada syndrome mutant. Yuan L; Koivumäki JT; Liang B; Lorentzen LG; Tang C; Andersen MN; Svendsen JH; Tfelt-Hansen J; Maleckar M; Schmitt N; Olesen MS; Jespersen T Am J Physiol Heart Circ Physiol; 2014 Apr; 306(8):H1204-12. PubMed ID: 24561865 [TBL] [Abstract][Full Text] [Related]
53. Nav 1.5 mutations linked to dilated cardiomyopathy phenotypes: Is the gating pore current the missing link? Gosselin-Badaroudine P; Moreau A; Chahine M Channels (Austin); 2014; 8(1):90-4. PubMed ID: 24300601 [TBL] [Abstract][Full Text] [Related]
54. Structure-based assessment of disease-related mutations in human voltage-gated sodium channels. Huang W; Liu M; Yan SF; Yan N Protein Cell; 2017 Jun; 8(6):401-438. PubMed ID: 28150151 [TBL] [Abstract][Full Text] [Related]
55. Ranolazine for Congenital Long-QT Syndrome Type III: Experimental and Long-Term Clinical Data. Chorin E; Hu D; Antzelevitch C; Hochstadt A; Belardinelli L; Zeltser D; Barajas-Martinez H; Rozovski U; Rosso R; Adler A; Benhorin J; Viskin S Circ Arrhythm Electrophysiol; 2016 Oct; 9(10):. PubMed ID: 27733495 [TBL] [Abstract][Full Text] [Related]
56. A novel mutation L619F in the cardiac Na+ channel SCN5A associated with long-QT syndrome (LQT3): a role for the I-II linker in inactivation gating. Wehrens XH; Rossenbacker T; Jongbloed RJ; Gewillig M; Heidbüchel H; Doevendans PA; Vos MA; Wellens HJ; Kass RS Hum Mutat; 2003 May; 21(5):552. PubMed ID: 12673799 [TBL] [Abstract][Full Text] [Related]
57. Inherited Brugada and long QT-3 syndrome mutations of a single residue of the cardiac sodium channel confer distinct channel and clinical phenotypes. Rivolta I; Abriel H; Tateyama M; Liu H; Memmi M; Vardas P; Napolitano C; Priori SG; Kass RS J Biol Chem; 2001 Aug; 276(33):30623-30. PubMed ID: 11410597 [TBL] [Abstract][Full Text] [Related]
58. Revealing the Concealed Nature of Long-QT Type 3 Syndrome. Greer-Short A; George SA; Poelzing S; Weinberg SH Circ Arrhythm Electrophysiol; 2017 Feb; 10(2):e004400. PubMed ID: 28213505 [TBL] [Abstract][Full Text] [Related]
59. Myotonic dystrophy type 1 mimics and exacerbates Brugada phenotype induced by Nav1.5 sodium channel loss-of-function mutation. Pambrun T; Mercier A; Chatelier A; Patri S; Schott JJ; Le Scouarnec S; Chahine M; Degand B; Bois P Heart Rhythm; 2014 Aug; 11(8):1393-400. PubMed ID: 24768612 [TBL] [Abstract][Full Text] [Related]
60. [Cardiac sodium channelopathy from bench to bedside]. Zhang YM; Zhou N Zhonghua Er Ke Za Zhi; 2013 Nov; 51(11):874-7. PubMed ID: 24484568 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]